Cornwall-born lynx kitten prepares for rewilding journey
A nine-month-old Carpathian lynx born at Newquay Zoo is starting her journey to be resettled into the wild, keepers say.The female cub, the first UK-bred lynx to join the initiative, was due to enter a week-long quarantine next week before her transfer to Germany at the end of the month, staff said.Following quarantine, the lynx will move to Zoo Karlsruhe in Germany, where she will undergo specialised training in hunting and survival skills within a semi-wild environment under the auspices of Europe's Linking Lynx programme. Her release into the wild was anticipated for autumn, contingent on her progress, the zoo said.
Dr Kathy Baker, research officer for the zoo's owners, the Wild Planet Trust, said: "This demonstrates how even smaller facilities like Newquay Zoo can make substantial contributions to international conservation initiatives. "We've planned every detail to give her the best chance of thriving in the wild."While the cub prepares for her journey, her parents, Kicsi and Onyx, remain on at Newquay Zoo and people can follow the lynx's progress on the zoo's social media channels.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
7 hours ago
- Daily Mail
Statins almost halve the risk of death in patients critically ill with sepsis
Taking statins can improve the chances of surviving sepsis by 40 per cent, a trial has found. Sepsis can occur when the body's immune system overreacts to an infection and attacks its own organs. It is notoriously difficult to spot because the telltale symptoms, such as a fever and muscle pain, can be easily mistaken for signs of a common cold or other infection. Statins lower cholesterol to prevent heart attacks and strokes and are taken by around 5 million adults in the UK. But experts say they have other benefits, including reducing inflammation and fighting bacteria that can ultimately lead to sepsis. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent (file image) In intensive care, 14.3 per cent of 6,000 sepsis patients given statins died within 28 days, compared with 23.4 per cent of 6,000 patients who were not. For those no longer in a critical condition, 11 per cent given statins died compared to 19 per cent who were not. Dr Caifeng Li, of Tianjin Medical University General Hospital in China and the study's author said: 'These results suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Researchers believe the drugs may help with sepsis by helping to combat bacteria directly, reducing the toll infection takes on the body. Earlier this year another study found the pills could also slash dementia risk – even in patients who don't have high cholesterol. The sepsis study, published in the journal Frontiers in Immunology, was based on data from thousands of patients at an Israeli hospital over a decade. Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'This study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.' Sepsis is known as the 'silent killer'. For every hour of delay in treatment, a patient's chance of dying increases 8 per cent. If caught early, it can be treated with antibiotics and fluids. Symptoms include slurred speech or confusion, shivering or muscle pain, passing no urine in a day, severe breathlessness and mottled or discoloured skin. Blood test to spot Alzheimer's early A Blood test for Alzheimer's can accurately detect the disease early, a study suggests. The test was 95 per cent accurate in identifying people with memory problems. It also scored 82 per cent for specificity, which means it was highly accurate in ruling out people without dementia. The study, published in the journal Alzheimer's and Dementia, found proteins amyloid beta 42/40 and p-tau217 in blood plasma can be examined to diagnose the condition. The study was carried out on more than 500 people in an outpatient memory clinic. The blood test has already been approved by the Food and Drug Administration regulator in the US.
BBC News
14 hours ago
- BBC News
Scientists create the 'world's smallest violin'
A team of scientists have created the 'world's smallest violin' - which is tinier than a speck of dust and needs a microscope to see it!The micro-violin was created using nanotechnology by a team at Loughborough measures 35 microns long and 13 microns wide - a micron is one millionth of a metre - for comparison a human hair is around 17 to 180 microns the tiny violin is just an image and not a playable instrument, so it cannot be officially confirmed as the world's smallest violin, the university said. The tiny violin was created to test the abilities of the university's new nanolithography system, which allows researchers to build and study tiny structures."Though creating the world's smallest violin may seem like fun and games, a lot of what we've learned in the process has actually laid the groundwork for the research we're now undertaking," said Professor Kelly Morrison, Head of the Physics department at Loughborough University."Our nanolithography system allows us to design experiments that probe materials in different ways – using light, magnetism, or electricity – and observe their responses."Once we understand how materials behave, we can start applying that knowledge to develop new technologies, whether it's improving computing efficiency or finding new ways to harvest energy," she said. How did they make it? To create the violin the researchers coated a tiny chip with two layers of gel-like material called a resist, before placing it under a nano-sculpting the machine uses a heated, needle-like tip to "write" very precise patterns on the nanoscale - in this case a violin shape - in a process called thermal scanning probe that a thin layer of platinum was poured into the carved out pattern to leave behind the finished whole process takes around three hours, but the research team's final version took several months to make, as they tested different techniques to get the best result.
Daily Mail
16 hours ago
- Daily Mail
Shock Covid warning: Ultra-catchy 'Nimbus' variant could trigger summer wave amid 97 per cent infection surge
A new highly contagious Covid variant could spark a wave of infections this summer, scientists have warned. Dubbed 'Nimbus', the strain is descended from the already super virulent Omicron and has already triggered a surge in cases in China, Singapore and Hong Kong. Data from the UK Health Security Agency (UKHSA) also shows 13 cases of Nimbus, known scientifically as N.B.1.8.1, have already been detected in England. And 25 British samples of the strain have been submitted to an international Covid database since the end of March. However, both figures are likely an underestimation of how far the variant has spread given how testing has been massively reduced from the height of the pandemic. Other UKHSA data show the percentage of people testing positive for Covid has risen to its highest point this year, and is already 97 per cent higher than the level recorded in March. Now, British scientists have warned Nimbus could lead to a surge in Covid cases in a matter of weeks, and have urged the vulnerable to get vaccinated. They warn that many people's immunity to the virus, built up from previous infections and older jabs, has likely faded meaning they could be at higher risk of falling ill. Professor Lawrence Young, a virologist at Warwick University, said Nimbus had the potential to drive a surge in cases as the weather warms up and people become more sociable. 'We are very likely to see a spike of infections over the next couple of months, possibly by later this month or in July. But it's difficult to predict the level of this infection wave,' he told The i Paper. 'Population immunity, either from vaccination or previous infection, is waning and, unlike other respiratory viruses such as flu, the Covid virus continues to spread in hot and humid weather,' he said. He added lab studies suggest Nimbus can infect human cells more efficiently than previous strains, and that it may have increased ability to dodge the immune system, making it more likely to infect people. There is currently no evidence that the strain is more likely to cause severe illness or death in those it infects, compared to previous strains. However, infection with the virus can still be deadly for more vulnerable groups. Covid was a factor in the deaths of just over 300 people in England in May, according to the latest official figures. Nimbus now accounts for 10.7 per cent of Covid infections worldwide, according to the World Health Organisation (WHO), compared to just 2.5 per cent a month prior. Last month the UN-body declared the strain a 'variant under monitoring'. This means that the WHO is tracking the virus, watching for signs it could pose a significant threat to the public which would promote it to a 'variant of concern'. Experts have also said that current Covid vaccines, which have been reformulated to combat Omicron descendants, are expected to remain effective against Nimbus. Symptoms of Nimbus do not appear to differ from other Covid variants and include fatigue, fever, muscle ache and a sore throat. UKHSA data on Covid tests, which goes up to June 1, show 6.1 per cent of the people who were tested that week were positive for the virus, the highest figure for 2025 so far. This is a seven per cent rise from last week's figure and a 97 per cent increase from that recorded at the beginning of March. Dr Gayatri Amirthalingam, UKHSA's deputy director, said the organisation was keeping a close eye on Nimbus. 'UKHSA is monitoring all available data relating to SARS-CoV-2 variants in the UK and abroad, and we continue to publish our findings in our regular Flu and Covid-19 surveillance reports,' she said. 'NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of all Covid-19 cases.' Currently adults over the age of 75, care home residents staff as well as people with a weakened immune system are eligible for a free Covid vaccine in Britain. UKHSA data suggests people who had a Covid jab as part of last spring's booster campaign were 45 per cent less likely to need hospital care for the virus in the weeks that followed compared to the unvaccinated. The agency has urged all people eligible for a vaccine to get jabbed to protect themselves from both NB.1.8.1 and Covid in general.
